Tempus AI Acquires Deep 6 AI to Advance Precision Medicine
Key Highlights Tempus AI (NASDAQ: TEM) has acquired Deep 6 AI, a leader in AI-powered precision research. Deep 6 AI…
Browsing Tag
Tempus AI
5 posts
Tempus AI Launches Immune Profile Score to Enhance Cancer Treatment
Key Highlights Tempus AI launches Immune Profile Score (IPS) for clinicians to advance cancer care. Prognostic tool for stage…
Tempus AI Launches Program to Enhance HER2 Testing Using AI Algorithms
Key Highlights Tempus AI introduces a new program to surface patients likely to benefit from HER2 testing. The…
Tempus AI and Remix Therapeutics Expand Strategic Collaboration
Key Highlights Tempus AI and Remix Therapeutics expand their strategic alliance. Remix utilizes Tempus’ multimodal data to advance REM-422 in…
Marc Yoskowitz Takes Helm as CEO at Evozyne to Propel AI-Driven Drug Discovery
Key Highlights Marc Yoskowitz appointed as CEO of Evozyne, bringing extensive leadership from Tempus AI, Pfizer, and McKinsey.…